PE20151884A1 - Formas cristalinas de inhibidores de tirosina cinasa y sus sales - Google Patents
Formas cristalinas de inhibidores de tirosina cinasa y sus salesInfo
- Publication number
- PE20151884A1 PE20151884A1 PE2015002014A PE2015002014A PE20151884A1 PE 20151884 A1 PE20151884 A1 PE 20151884A1 PE 2015002014 A PE2015002014 A PE 2015002014A PE 2015002014 A PE2015002014 A PE 2015002014A PE 20151884 A1 PE20151884 A1 PE 20151884A1
- Authority
- PE
- Peru
- Prior art keywords
- tyrosine kinase
- salts
- kinase inhibitors
- crystalline forms
- refers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801112P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151884A1 true PE20151884A1 (es) | 2016-01-08 |
Family
ID=51529961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002014A PE20151884A1 (es) | 2013-03-15 | 2014-03-14 | Formas cristalinas de inhibidores de tirosina cinasa y sus sales |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8999992B2 (enExample) |
| EP (1) | EP2970148A4 (enExample) |
| JP (1) | JP2016513704A (enExample) |
| KR (1) | KR20150142688A (enExample) |
| CN (1) | CN105377821A (enExample) |
| AU (1) | AU2014239254B2 (enExample) |
| BR (1) | BR112015022631A2 (enExample) |
| CA (1) | CA2904403A1 (enExample) |
| CL (1) | CL2015002593A1 (enExample) |
| CR (1) | CR20150560A (enExample) |
| EA (1) | EA201591684A1 (enExample) |
| GT (1) | GT201500292A (enExample) |
| HK (1) | HK1220193A1 (enExample) |
| MX (1) | MX2015012403A (enExample) |
| NI (1) | NI201500139A (enExample) |
| PE (1) | PE20151884A1 (enExample) |
| PH (1) | PH12015502110A1 (enExample) |
| SG (2) | SG10201707484UA (enExample) |
| SV (1) | SV2015005074A (enExample) |
| TN (1) | TN2015000407A1 (enExample) |
| UA (1) | UA116466C2 (enExample) |
| WO (1) | WO2014152663A1 (enExample) |
| ZA (1) | ZA201507154B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016116516A (ru) | 2008-12-08 | 2018-12-07 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
| US8999992B2 (en) * | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| CA2962206A1 (en) * | 2014-09-17 | 2016-03-24 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
| US20180370926A1 (en) * | 2015-08-07 | 2018-12-27 | Purdue Pharma L.P. | Process of preparing tyrosine kinase inhibitor |
| KR102717072B1 (ko) | 2017-10-18 | 2024-10-15 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| WO2019159097A1 (en) * | 2018-02-14 | 2019-08-22 | Sun Pharmaceutical Industries Limited | Crystalline polymorphic forms of acalabrutinib |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US4337341A (en) * | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| RU2065438C1 (ru) | 1993-12-22 | 1996-08-20 | Институт химии природного органического сырья СО РАН | Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она |
| US6635626B1 (en) | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| US6476032B2 (en) | 1998-12-17 | 2002-11-05 | Wyeth | 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives |
| PL352680A1 (en) | 1999-06-03 | 2003-09-08 | Knoll Gmbh | Benzothiazinone and benzoxazinone compounds |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| US7015231B2 (en) | 2001-09-27 | 2006-03-21 | Smithkline Beecham Corporation | Chemical compounds |
| KR20030095729A (ko) | 2002-06-14 | 2003-12-24 | 크리스탈지노믹스(주) | 2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5Ｈ-티아졸로[3,2-ａ]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1Ｂ 활성 억제용 약학 조성물 |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| WO2004032870A2 (en) | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
| IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| ATE422895T1 (de) | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| EP1663962A4 (en) | 2003-08-22 | 2007-08-22 | Dendreon Corp | COMPOSITIONS AND METHODS FOR TREATING A DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION |
| WO2008021463A2 (en) | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| KR101637908B1 (ko) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
| WO2006007864A1 (en) | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
| US7671077B2 (en) * | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
| US7718674B2 (en) | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
| CA2595290C (en) | 2005-01-19 | 2013-06-25 | Mgi Gp, Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp |
| FR2881138B1 (fr) | 2005-01-27 | 2007-03-02 | Servier Lab | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| JP5191155B2 (ja) | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
| JP2007303392A (ja) | 2006-05-11 | 2007-11-22 | Honda Motor Co Ltd | 気体燃料内燃機関の制御装置 |
| WO2008053863A1 (en) | 2006-10-30 | 2008-05-08 | Santen Pharmaceutical Co., Ltd. | Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton |
| MX2009007053A (es) | 2006-12-28 | 2009-07-09 | Abbott Lab | Inhibidores de poli (adp-ribosa) polimerasa. |
| EP2218713A1 (en) | 2007-08-17 | 2010-08-18 | Hetero Drugs Limited | Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B |
| EP2227859B1 (en) | 2007-11-16 | 2017-11-01 | Gula Consulting Limited Liability Company | Filter design methods and filters based on metamaterial structures |
| RU2016116516A (ru) | 2008-12-08 | 2018-12-07 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
| EP2239256A1 (en) * | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| US8853235B2 (en) * | 2009-11-23 | 2014-10-07 | Senhwa Biosciences, Inc. | Polymorphs and salts of a kinase inhibitor |
| CN102947308A (zh) | 2010-06-23 | 2013-02-27 | Osi药物有限责任公司 | Osi-906的多晶型物 |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| US9376406B2 (en) | 2011-03-03 | 2016-06-28 | Indiana University Research And Technology Corporation | uPAR-uPA interaction inhibitors and methods for treating cancer |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| CA2962206A1 (en) | 2014-09-17 | 2016-03-24 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
-
2014
- 2014-03-13 US US14/208,244 patent/US8999992B2/en active Active
- 2014-03-14 HK HK16108270.6A patent/HK1220193A1/zh unknown
- 2014-03-14 AU AU2014239254A patent/AU2014239254B2/en not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/027591 patent/WO2014152663A1/en not_active Ceased
- 2014-03-14 JP JP2016502487A patent/JP2016513704A/ja active Pending
- 2014-03-14 CA CA2904403A patent/CA2904403A1/en not_active Abandoned
- 2014-03-14 SG SG10201707484UA patent/SG10201707484UA/en unknown
- 2014-03-14 KR KR1020157029442A patent/KR20150142688A/ko not_active Withdrawn
- 2014-03-14 CN CN201480015906.9A patent/CN105377821A/zh active Pending
- 2014-03-14 BR BR112015022631A patent/BR112015022631A2/pt not_active IP Right Cessation
- 2014-03-14 EP EP14770743.4A patent/EP2970148A4/en not_active Withdrawn
- 2014-03-14 SG SG11201507516XA patent/SG11201507516XA/en unknown
- 2014-03-14 US US14/772,264 patent/US9718794B2/en active Active
- 2014-03-14 UA UAA201509781A patent/UA116466C2/uk unknown
- 2014-03-14 CR CR20150560A patent/CR20150560A/es unknown
- 2014-03-14 PE PE2015002014A patent/PE20151884A1/es not_active Application Discontinuation
- 2014-03-14 EA EA201591684A patent/EA201591684A1/ru unknown
- 2014-03-14 MX MX2015012403A patent/MX2015012403A/es unknown
-
2015
- 2015-03-02 US US14/635,635 patent/US9388146B2/en active Active
- 2015-09-10 TN TN2015000407A patent/TN2015000407A1/en unknown
- 2015-09-10 CL CL2015002593A patent/CL2015002593A1/es unknown
- 2015-09-11 NI NI201500139A patent/NI201500139A/es unknown
- 2015-09-14 SV SV2015005074A patent/SV2015005074A/es unknown
- 2015-09-14 GT GT201500292A patent/GT201500292A/es unknown
- 2015-09-14 PH PH12015502110A patent/PH12015502110A1/en unknown
- 2015-09-28 ZA ZA2015/07154A patent/ZA201507154B/en unknown
-
2016
- 2016-06-17 US US15/185,754 patent/US9993473B2/en active Active
-
2017
- 2017-07-13 US US15/648,527 patent/US10124002B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201500139A (es) | Formas cristalinas de inhibidores de tirosina cinasa y sus sales | |
| CU24621B1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| CU24517B1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CU20160149A7 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
| CL2017001675A1 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| CR20160296A (es) | Benzamidas sustituidas y métodos para usarlas | |
| MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
| ECSP16071151A (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
| CR20140464A (es) | Compuestos de heterociclilo | |
| MX2017000485A (es) | Espirocicloheptanos como inhibidores de la cinasa rho (rock). | |
| DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
| MX2019013645A (es) | Inhibidores de quinasa y usos de los mismos. | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| DOP2016000242A (es) | Uso de compuestos heterocíclicos para controlar nematodos | |
| BR112015004111A2 (pt) | novos derivados bicíclicos | |
| EA201790112A1 (ru) | Гетероциклические соединения и их применение в качестве ингибиторов орфанного рецептора гамма-t, родственного рецепторам ретиноидов (ror) | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| EA201891768A1 (ru) | Кристаллическая форма a агониста tlr7, ее способ получения и использование | |
| DOP2017000289A (es) | Moduladores de receptor nuclear | |
| MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
| CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |